ATC Group: M05BC Bone morphogenetic proteins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M05BC in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M05 Drugs for treatment of bone diseases
3 M05B Drugs affecting bone structure and mineralization
4 M05BC Bone morphogenetic proteins

Group M05BC contents

Code Title
M05BC01 Dibotermin alfa
M05BC02 Eptotermin alfa

Active ingredients in M05BC

Active Ingredient

Dibotermin alfa is an osteoinductive protein that results in the induction of new bone tissue at the site of implantation. Dibotermin alfa binds to receptors on the surface of mesenchymal cells and causes cells to differentiate into cartilage- and bone-forming cells. The differentiated cells form trabecular bone as the matrix is degraded, with vascular invasion evident at the same time.

Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle. Once bound at the cell surface, the active substance induces a cascade of cellular events leading to the formation of chondroblasts and osteoblasts, which play a key role in the bone formation process.

Related product monographs

Document Type Information Source  
 INDUCTOS Powder, solvent and matrix for implantation matrix MPI, EU: SmPC European Medicines Agency (EU)
 OSIGRAFT Powder for suspension for implantation MPI, EU: SmPC European Medicines Agency (EU)